New uses for phenylketone carboxylate compounds and substituted aromatic compounds of Formula I Formula I.1 Formula I.2 Formula IA Formula IB Formula IC and Formula II and their pharmaceutical acceptable salts for the treatment of cancer. The use of a combination of two of these compounds is described and the use of the combination of one of these compounds with an anticancer agent such as decarbazine doxorubicin daunorubicin cyclophosphamide busulfex busulfan vinblastine vincristine bleomycin e...

New uses for phenylketone carboxylate compounds and substituted aromatic compounds of Formula I Formula I.1 Formula I.2 Formula IA Formula IB Formula IC and Formula II and their pharmaceutical acceptable salts for the treatment of cancer. The use of a combination of two of these compounds is described and the use of the combination of one of these compounds with an anticancer agent such as decarbazine doxorubicin daunorubicin cyclophosphamide busulfex busulfan vinblastine vincristine bleomycin e...

598890 Disclosed herein are compounds of formula (I) U1-M-U2 wherein the variables are defined in the specification the use of said compounds in the treatment of cancer specifically by sensitising a cell to an apoptotic signal. Additionally said compounds may be used for sequential or concomitant use with a pharmaceutical compound which induces an apoptotic signal such as cytarabine fludarabine 5-fluoro-2'-deoxyuridine 5 gemcitabine methotrexate bleomycin cisplatin cyclophosphamide adriamycin (d...

New uses for phenylketone carboxylate compounds and substituted aromatic compounds of Formula I Formula I.1 Formula I.2 Formula IA Formula IB Formula IC and Formula II and their pharmaceutical acceptable salts for the treatment of cancer. The use of a combination of two of these compounds is described and the use of the combination of one of these compounds with an anticancer agent such as decarbazine doxorubicin daunorubicin cyclophosphamide busulfex busulfan vinblastine vincristine bleomycin e...

New uses for phenylketone carboxylate compounds and substituted aromatic compounds of Formula I Formula I.1 Formula I.2 Formula IA Formula IB Formula IC and Formula II and their pharmaceutical acceptable salts for the treatment of cancer. The use of a combination of two of these compounds is described and the use of the combination of one of these compounds with an anticancer agent such as decarbazine doxorubicin daunorubicin cyclophosphamide busulfex busulfan vinblastine vincristine bleomycin e...

New uses for phenylketone carboxylate compounds and substituted aromatic compounds of Formula I Formula I.1 Formula I.2 Formula IA Formula IB Formula IC and Formula II and their pharmaceutical acceptable salts for the treatment of cancer. The use of a combination of two of these compounds is described and the use of the combination of one of these compounds with an anticancer agent such as decarbazine doxorubicin daunorubicin cyclophosphamide busulfex busulfan vinblastine vincristine bleomycin e...

The disclosure relates to compounds and compositions for bone formation fracture treatment bone grafting bone fusion cartilage maintenance and repair and methods related thereto. In certain embodiments the disclosure relates to compositions comprising one or more compound(s) disclosed herein such as clotrimazole honokiol magnolol tacrolimus pimecrolimus sirolimus everolimus temsirolimus spironolactone fluticasone fluticasone propionate fluticasone furoate linezolid telmisartan chlorambucil retin...

PROBLEM TO BE SOLVED: To provide a method for treating cervical cancer or cells infected with human papilloma virus. SOLUTION: Interleukin-20 (IL-20) can be administered alone or in conjunction with radiation or chemotherapeutic agents or surgical excision of the involved cells or lesions. The chemotherapeutic agent is selected from the group consisting of bleomycin chlorambucil epirubicin 5-fluorouracil ifosfamide mitomycin methotrexate vincristine cisplatin and vinblastine. COPYRIGHT: (C)201...